Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue (ENER-G)

This study has been completed.
Elan Pharmaceuticals
Information provided by:
Biogen Identifier:
First received: April 18, 2007
Last updated: July 7, 2011
Last verified: July 2011
This study aims to study the effects of TYSABRI® treatment on fatigue and cognition in patients with relapsing forms of MS.

Multiple Sclerosis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Multi-center, Open-Label Study to Evaluate the Effects of Natalizumab Treatment on Fatigue and Cognition in Subjects With Relapsing Forms of MS

Resource links provided by NLM:

Further study details as provided by Biogen:

Primary Outcome Measures:
  • Visual Analog Scale for Fatigue (VAS-F) [ Time Frame: at three months after initiating treatment with TYSABRI® ]

Enrollment: 200
Study Start Date: September 2007
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Detailed Description:

TYSABRI® treatment has already demonstrated significant improvement in the quality of life (QoL) of patients with MS. In particular, TYSABRI® add-on treatment to interferon beta-1a has demonstrated improvement in fatigue as measured by the Modified Fatigue Impact Scale (MFIS). Both patients and neurologists report that patients have experienced significant improvements in fatigue shortly after initiating TYSABRI® treatment. Fatigue is both a common and a disabling symptom of MS. Further, there is evidence that fatigue contributes to cognitive difficulties in patients with MS. This study aims to study the effects of TYSABRI® treatment on fatigue and cognition in patients with relapsing forms of MS.

The primary objective of this study is to determine the effects of TYSABRI® treatment on fatigue in subjects with relapsing forms of MS as measured by changes in patient-reported Visual Analog Scale for Fatigue (VAS-F).

Primary endpoint is the change in the following:

1. Visual Analog Scale for Fatigue (VAS-F) at three months after initiating treatment with TYSABRI®.

Secondary objectives are to measure changes in patient-reported Modified Fatigue Impact Scale (MFIS) and Fatigue Severity Scale (FSS).

Secondary endpoints are changes in the following:

  1. Modified Fatigue Impact Scale (MFIS)
  2. Fatigue Severity Scale (FSS)

The tertiary objective of this study is to explore for any effects of TYSABRI® treatment on cognition by assessing changes in the Automated Neuropsychology Assessment Metrics (ANAM).

Tertiary endpoints are changes in the Automated Neuropsychology Assessment Metrics (ANAM) consisting of:

  • Traditional Continuous Performance Test
  • Running Memory Continuous Performance Test
  • Simple Response Time
  • Procedural Response Time
  • Coding Substitution
  • Mathematics
  • Logical Relations
  • Matching-to-Sample
  • Stanford Sleepiness Scale

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
multicenter clinic patients

Inclusion Criteria:

  1. Diagnosis of relapsing forms of MS.
  2. Patients having an inadequate response to or unable to tolerate alternate MS therapies.
  3. Patient must be enrolled in the TOUCH prescribing program.
  4. Recent MRI as part of the TOUCH prescribing program.
  5. Patient must be between 18 and 55 years of age, inclusive.
  6. EDSS between 0 and 5.5, inclusive.
  7. Able to provide written informed consent.
  8. Capable of completing the fatigue (MFIS, FSS, and VAS-F) and cognition (ANAM) sessions.
  9. A baseline VAS-F average score of > 60.
  10. Patient must be naÃ-ve to TYSABRI® treatment.

Exclusion Criteria:

  1. Patients not enrolled in the TOUCH prescribing program.
  2. History or presence of progressive multifocal leukoencephalopathy (PML).
  3. Diagnosis of primary progressive MS (PPMS) or secondary progressive MS (SPMS) without relapses.
  4. Immunocompromised in the judgment of the investigator.
  5. Allergy or hypersensitivity to TYSABRI®.
  6. Prior history or current presence of a clinically significant medical illness or laboratory abnormality, including any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, and/or other major disease, that, in the opinion of the investigator, would preclude the administration of TYSABRI®.
  7. Women pregnant, breast feeding, or planning to become pregnant and women who are not postmenopausal or surgically sterile, and unwilling to practice contraception.
  8. A baseline average VAS-F score of < 60.
  9. Problems with upper extremity dexterity that could preclude usage of a computer mouse.
  10. With educational completion below 8th grade school equivalent or non-fluent in English.
  11. Any other reason, in the opinion of both the Investigator and/or Sponsor, the patient is determined not suitable for study participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00464074

  Show 31 Study Locations
Sponsors and Collaborators
Elan Pharmaceuticals
  More Information

Responsible Party: Biogen Idec MD, Biogen Idec Identifier: NCT00464074     History of Changes
Other Study ID Numbers: 001-06-NAT
Study First Received: April 18, 2007
Last Updated: July 7, 2011

Keywords provided by Biogen:

Additional relevant MeSH terms:
Multiple Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Signs and Symptoms
Immunologic Factors
Physiological Effects of Drugs processed this record on April 25, 2017